Market capitalization | $234.78m |
Enterprise Value | $85.13m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 28.57 |
P/S ratio (TTM) P/S ratio | 78.79 |
P/B ratio (TTM) P/B ratio | 1.53 |
Revenue (TTM) Revenue | $2.98m |
EBIT (operating result TTM) EBIT | $-202.47m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
11 Analysts have issued a Prime Medicine forecast:
11 Analysts have issued a Prime Medicine forecast:
Dec '24 |
+/-
%
|
||
Revenue | 2.98 2.98 |
-
|
|
Gross Profit | -3.15 -3.15 |
78%
78%
|
|
EBITDA | -196 -196 |
11%
11%
|
EBIT (Operating Income) EBIT | -202 -202 |
6%
6%
|
Net Profit | -196 -196 |
1%
1%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Keith Gottesdiener |
Employees | 214 |
Founded | 2019 |
Website | www.primemedicine.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.